

APA-1  
Revised 4/2018

TRANSMITTAL SHEET FOR  
NOTICE OF INTENDED ACTION

Control 540 Department or Agency Alabama State Board of Medical Examiners  
Rule No. 540-X-17-.05  
Rule Title: Continued Use of a Controlled Substance for the Purpose of Weight Reduction or Treatment of Obesity

New  Amend  Repeal  Adopt by Reference

Would the absence of the proposed rule significantly harm or endanger the public health, welfare, or safety? NO

Is there a reasonable relationship between the state's police power and the protection of the public health, safety, or welfare? YES

Is there another, less restrictive method of regulation available that could adequately protect the public? NO

Does the proposed rule have the effect of directly or indirectly increasing the costs of any goods or services involved and, if so, to what degree? NO

Is the increase in cost, if any, more harmful to the public than the harm that might result from the absence of the proposed rule? NO

Are all facets of the rulemaking process designed solely for the purpose of, and so they have, as their primary effect, the protection of the public? YES

Does the proposed action relate to or affect in any manner any litigation which the agency is a party to concerning the subject matter of the proposed rule? NO

\*\*\*\*\*  
Does the proposed rule have an economic impact? NO

If the proposed rule has an economic impact, the proposed rule is required to be accompanied by a fiscal note prepared in accordance with subsection (f) of Section 41-22-23, Code of Alabama 1975.

\*\*\*\*\*  
Certification of Authorized Official

I certify that the attached proposed rule has been proposed in full compliance with the requirements of Chapter 22, Title 41, Code of Alabama 1975, and that it conforms to all applicable filing requirements of the Administrative Procedure Division of the Legislative Services Agency.

Signature of certifying officer 

Date: June 17, 2020

REC'D & FILED  
JUN 17 2020  
LEGISLATIVE SVC AGENCY

APA-2

**ALABAMA STATE BOARD OF MEDICAL EXAMINERS  
NOTICE OF INTENDED ACTION**

**AGENCY NAME:** Alabama Board of Medical Examiners

**RULE NO. & TITLE:** 540-X-17-.05, Continued Use of a Controlled Substance for the Purpose of Weight Reduction or Treatment of Obesity

**INTENDED ACTION:** Amend the Rule

**SUBSTANCE OF PROPOSED ACTION:** Amend the rule regarding the use of non-controlled drugs for weight reduction/treatment of obesity.

**TIME, PLACE, MANNER OF PRESENTING VIEWS:** All interested persons may submit data, views, or arguments concerning the proposed amended rule(s) and regulation(s) in writing to: Carla H. Kruger, Office of the General Counsel, Alabama State Board of Medical Examiners, Post Office Box 946, Montgomery, Alabama 36101-0946, by mail or in person between the hours of 8:30 a.m. and 4:30 p.m., Monday through Friday, until and including August 4, 2020. Persons wishing to obtain copies of the text of this rule and submit data, views, or comments or arguments orally should contact Carla H. Kruger by telephone (334-242-4116) during said period in order to set up an appointment for a hearing respecting such oral data, views, or arguments. Copies can also be obtained at the Board's web site, [www.albme.org](http://www.albme.org).

**FINAL DATE FOR COMMENT AND COMPLETION OF NOTICE:** August 4, 2020

**CONTACT PERSON AT AGENCY:** Carla H. Kruger



(Signature of officer authorized  
to promulgate and adopt  
rules or his or her deputy)

540-X-17-.05 Continued Use of a Controlled Substance for the Purpose of Weight Reduction or Treatment of Obesity.

(1) A physician should not prescribe, order or dispense a controlled substance for the purpose of weight reduction or treatment of obesity in an amount greater than a thirty-five (35) day supply.

(2) Within the first thirty-five (35) days following initiation of a controlled substance for the purpose of weight reduction or treatment of obesity, the patient should be seen by the prescribing physician, a physician assistant supervised by the prescribing physician, or a certified registered nurse practitioner collaborating with the prescribing physician, and a recording should be made of weight, blood pressure, pulse, and any other tests which may be necessary for monitoring potential adverse effects of drug therapy.

(3) Continuation of the prescribing, ordering, dispensing or administering of a controlled substance to a patient for the purpose of weight reduction or treatment of obesity should occur only if the patient has continued progress toward achieving or maintaining medically established goals and has no significant adverse effects from the medication.

(4) A patient continued on a controlled substance for the purpose of weight reduction or treatment of obesity should undergo an in-person re-evaluation at least once every thirty-five (35) days. Once medically established goals have been met for an individual patient, it is strongly recommended that reduced dosing and drug holidays be implemented for those patients who need maintenance medication.

(5) If the re-evaluation is delegated to a physician assistant or certified registered nurse practitioner, then the prescribing physician should personally review the

resulting medical records prior to the continuance of the patient on a controlled substance for the purpose of weight reduction or treatment of obesity.

(6) For the prescribing of only non-controlled drugs for weight reduction or the treatment of obesity ~~the drugs, Qsymia(TM) and Belviq®~~, the following applies:

(a) Five (5) Refills of non-controlled drugs for weight reduction or the treatment of obesity ~~Qsymia(TM) and Belviq®~~ are allowed after an initial ~~Qsymia(TM) or Belviq®~~ prescription and one follow up visit for an in-person re-evaluation. ~~For non-controlled drugs for weight reduction or the treatment of obesity~~ ~~Qsymia(TM) and Belviq®, five (5) refills are allowed.~~ The five (5) refills shall not extend past a period of six (6) months from the date of issue of the original prescription.

(b) Continued prescribing/refills of non-controlled drugs for weight reduction or the treatment of obesity ~~Qsymia(TM)~~ ~~must be occur~~ in accordance with the any Risk Evaluation and Mitigation Strategy (REMS) required by the Federal Food and Drug Administration (FDA) ~~for Qsymia(TM)~~.

(c) Refills allowed pursuant to this rule are specific for non-controlled drugs for weight reduction or the treatment of obesity ~~the brand name drugs Qsymia(TM) and Belviq®, and refills are not allowed for generic substitutes or for individual prescriptions of phentermine.~~ This rule in no way amends, alters, or applies to the refilling of individual prescriptions for controlled substances.

**Authors:** Alabama Board of Medical Examiners

**Statutory Authority:** Code of Alabama § 34-24-53

**History:** Approved for publication: October 19, 2011. Effective Date:

January 20, 2012. Amended/approved for publication: January 16, 2013.

Effective Date: April 25, 2013. Amended/approved for publication:  
January 15, 2014. Further amended/approved for publication: April 16,  
2014. Further amended/approved for publication: May 22, 2014.  
Effective Date: September 25, 2014. Amended/approved for publication:  
February 17, 2016. Effective Date: May 31, 2016. Amended/Approved:  
June 17, 2020.